This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Celgene
Sponsor:
Information provided by (Responsible Party):
Celgene
ClinicalTrials.gov Identifier:
NCT02367196
First received: February 13, 2015
Last updated: May 9, 2017
Last verified: May 2017
  Purpose
CC-90002-ST -001 is an open-label, Phase 1, dose escalation and expansion clinical study in subjects advanced, refractory solid and hematologic cancers.

Condition Intervention Phase
Hematologic Neoplasms Drug: CC-90002 Drug: Rituximab Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers

Resource links provided by NLM:


Further study details as provided by Celgene:

Primary Outcome Measures:
  • Dose‐Limiting Toxicity (DLT) [ Time Frame: Up to 18 months ]
    Number of participants with a DLT

  • Non-Tolerated Dose (NTD) - Part A [ Time Frame: Up to 18 months ]
    Dose at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1.

  • Maximum Tolerated Dose (MTD) - Part A [ Time Frame: Up to 18 months ]
    Dose that is the last dose level below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during Cycle 1.

  • Non-Tolerated Dose (NTD) - Part B [ Time Frame: Up to 24 months ]
    Dose at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1.

  • Maximum Tolerated Dose (MTD) - Part B [ Time Frame: Up to 24 months ]
    Dose that is the last dose level below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during Cycle 1.


Secondary Outcome Measures:
  • Antitumor efficacy [ Time Frame: Up to 36 months ]
    Determined by response rates of each tumor type using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and other tumor-appropriate response criteria.

  • Pharmacokinetics ‐ Cmax [ Time Frame: Cycle 1 and beyond; and after discontinuation ]
    Maximum observed concentration in serum

  • Pharmacokinetics - AUC [ Time Frame: Cycle 1 and beyond; and after discontinuation ]
    Area under the serum concentration - time curve

  • Pharmacokinetics - tmax [ Time Frame: Cycle 1 and beyond; and after discontinuation ]
    Time to peak (maximum) serum concentration

  • Pharmacokinetics ‐ T1/2 [ Time Frame: Cycle 1 and beyond; and after discontinuation ]
    Terminal half‐life (T1/2)

  • Pharmacokinetics - CL [ Time Frame: Cycle 1 and beyond; and after discontinuation ]
    Total body clearance of the drug from serum

  • Pharmacokinetics - Vmax [ Time Frame: Cycle 1 and beyond; and after discontinuation ]
    Volume of distribution at steady-state

  • Anti-Drug Antibodies (ADAs) [ Time Frame: Cycle 1 and beyond; and after discontinuation ]
    Determine the presence and frequency of anti-drug antibodies

  • Overall Survival - Part B [ Time Frame: Up to 2 years ]
    Measured as the time from the first dose of CC-90002 to death due to any cause.

  • Progression-free survival- Part B [ Time Frame: Up to 2 years ]
    Defined as the time from the first dose of CC-90002 to the first occurrence of disease progression or death from any cause


Estimated Enrollment: 65
Actual Study Start Date: March 30, 2015
Estimated Study Completion Date: January 21, 2018
Estimated Primary Completion Date: January 21, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CC-90002 +/- Rituximab
CC-90002 by intravenous (IV) infusion on a 28 day cycle (PartA); CC-90002 in combination with Rituximab by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL (Part B)
Drug: CC-90002 Drug: Rituximab

Detailed Description:
CC-90002-ST-001 is an open-label, Phase 1, dose escalation and expansion, first in human (FIH) clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with advanced, refractory solid and hematologic cancers. The study will be conducted in two parts. Part A dose escalation phase will explore escalating dose cohorts of the study drug CC-90002. Following completion of Part A, CC-90002 in combination with rituximab will be administered in subjects with CD20-positive non-Hodgkin's lymphoma (NHL) in Part B dose escalation and expansion phase.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- 1. Men and women, 18 years or older, with advanced, relapsed or refractory solid tumors, Multiple Myeloma (MM) or non-Hodgkin's lymphoma (NHL) in Part A. In Part B, relapsed or refractory CD20-positive NHL subjects only.

2. At least one site of measurable disease in subjects with solid tumors and NHL.

3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. 4. Subjects must have adequate hematopoietic, liver, renal and coagulation function as assessed by specific laboratory criteria.

5. Females and males must agree to contraceptive methods and avoid conceiving throughout the study, and for up to 8 weeks following the last dose of CC-90002. If participating in Part B, females of child bearing potential should continue to use effective contraceptive methods for 12 months following treatment with rituximab

Exclusion Criteria:

  1. High grade lymphomas (Burkitts or lymphoblastic), plasma cell leukemia.
  2. High grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell tumors, neuroblastoma) with extensive tumor burden.
  3. Symptomatic central nervous system involvement.
  4. Impaired cardiac function or clinically significant cardiac disease.
  5. Prior Red blood cell (RBC) transfusion < 3 months prior to starting CC-90002.
  6. Prior autologous stem cell transplant ≤ 3 months prior to starting CC-90002.
  7. Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-90002.
  8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting CC-90002, whichever is shorter.
  9. Major surgery ≤ 2 weeks prior to starting CC-90002.
  10. Pregnant or nursing females.
  11. Known HIV infection.
  12. Known chronic hepatitis B or C (HBV/HCV) infection.
  13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
  14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
  15. History of concurrent second cancers requiring active, ongoing systemic treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02367196

Contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
United States, Arizona
Scottsdale Healthcare Research Institute Recruiting
Scottsdale, Arizona, United States, 85258
University of Arizona Cancer Center Not yet recruiting
Tucson, Arizona, United States, 85724
United States, California
University of California San Francisco Recruiting
San Francisco, California, United States, 94143
United States, Connecticut
Yale University School of Medicine Not yet recruiting
New Haven, Connecticut, United States, 06520-8073
United States, Texas
South Texas Accelerated Research Therapeutics Recruiting
San Antonio, Texas, United States, 78229
Spain
Hospital Universitari Germans Trias i Pujol Can Ruti Recruiting
Badalona (Barcelona), Spain, 08916
Hospital Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Hospital Universitario Fundacion Jimenez Diaz Recruiting
Madrid, Spain, 28040
Hospital Universitario de Salamanca Recruiting
Salamanca, Spain, 37007
Sponsors and Collaborators
Celgene
Investigators
Study Director: Michael Burgess, MD, PhD Celgene
  More Information

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT02367196     History of Changes
Other Study ID Numbers: CC-90002-ST-001
2015-000101-39 ( EudraCT Number )
Study First Received: February 13, 2015
Last Updated: May 9, 2017

Keywords provided by Celgene:
CC-90002
Monoclonal
Antibody
CD47
Advanced
Solid Cancers
Hematologic Cancers

Additional relevant MeSH terms:
Hematologic Neoplasms
Neoplasms by Site
Neoplasms
Hematologic Diseases
Rituximab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on July 21, 2017